vimarsana.com

Latest Breaking News On - Longer treatment duration may - Page 1 : vimarsana.com

Aeglea BioTherapeutics : Costs Associated with Exit/Disposal - Form 8-K

Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to. | April 12, 2023

United statesMichaelc hanleyKelly bootheCortney caudillLinda neumanAeglea biotherapeuticsJeffrey goldbergExchange commissionEuropean medicines agencyWedbush securities incInvestor relations corporate communicationsAeglea biotherapeutics incCompany annual report on formOngoing phaseClassical homocystinuriaBegins process

Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives

Results from Cohorts 1 and 2 Showed a Dose-Dependent Reduction in Total Homocysteine Levels Results from Cohort 3 Indicated Additional Dose Exploration and Data from Longer Treatment Duration May. | April 12, 2023

United statesLinda neumanAeglea biotherapeuticsJeffrey goldbergCortney caudillMichaelc hanleyAeglea biotherapeutics incExchange commissionWedbush securities incCompany annual report on formEuropean medicines agencyDose dependent reductionTotal homocysteine levelsAdditional dose explorationLonger treatment duration mayPercent change

vimarsana © 2020. All Rights Reserved.